Dr Kola Tytler MBBS CertHE MBA MRCGPClinical Lead • iatroX
Daridorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.
While the provided literature discusses orexin receptor antagonists in the context of adjunctive therapy for difficult-to-treat depression Thase 2025, this specific indication is not supported by the current UK guideline information for daridorexant.
Key References
- CKS - Insomnia
- CKS - Restless legs syndrome
- CG78 - Borderline personality disorder: recognition and management
- NG202 - Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s
- (Thase, 2025): A new direction for adjunctive therapy of difficult-to-treat depression: examining the role of orexin receptor antagonists.